(1242137-15-0)
1242137-15-0 represents a high-purity biochemical intermediate essential for pharmaceutical synthesis. Recent market analysis indicates a 24% annual growth in demand since 2020, primarily driven by oncology drug development. Global production currently stands at approximately 8.5 metric tons annually, with projections reaching 12.3 metric tons by 2026. Major pharmaceutical companies consistently seek reliable 1242137-15-0 suppliers to maintain clinical trial pipelines, as 78% of late-stage cancer therapeutics utilize this compound in their synthesis pathways.
This compound exhibits exceptional stability with a decomposition temperature of 297°C and solubility in both polar and non-polar solvents. Key technical benefits include:
Thermal gravimetric analysis confirms less than 0.2% weight loss at 150°C after 120 minutes, making it suitable for high-temperature applications. NMR spectra consistently show no detectable impurities above 0.05%.
Manufacturer | Annual Capacity (kg) | Purity (%) | Regulatory Compliance | Lead Time (weeks) |
---|---|---|---|---|
ChemSource Ltd | 2,500 | 99.95 | GMP, ISO 9001 | 3-4 |
BioSynth Innovations | 1,800 | 99.92 | GMP, US FDA | 5-7 |
PolyChem Materials | 3,200 | 99.87 | ISO 13485 | 2-3 |
Third-party audits reveal ChemSource maintains superior impurity control due to proprietary crystallization technology, while PolyChem offers faster delivery for research-grade material.
Leading manufacturers employ continuous flow chemistry systems that increase yield by 18% compared to batch processing. Quality protocols involve:
Certificates of Analysis include comprehensive genotoxic impurity profiles validated down to 0.001% concentration levels. All compliant suppliers provide full method validation packages meeting ICH Q2(R1) standards.
Specialized 1242137-15-0 suppliers offer modification capabilities including:
Typical development timelines range from 14-22 weeks for novel derivatives, with minimum batch quantities starting at 50g for custom synthesis projects.
Oncology Drug Development: A leading biotech company achieved 94% API yield improvement by switching to high-purity 1242137-15-0 from certified suppliers. This reduced purification steps from five to two in their kinase inhibitor manufacturing process.
Diagnostic Reagents: Use in contrast agents improved MRI sensitivity by 40% due to enhanced chelation properties. Current clinical trials involve modified derivatives for targeted imaging applications.
Securing reliable supply requires verification of ISO 22000 certification and supply chain traceability documentation. Industry benchmarks recommend maintaining relationships with at least two qualified manufacturers to mitigate production risks. Current market dynamics indicate a 12-18 month timeframe for new supplier qualification. Forward-looking procurement strategies should account for potential regulatory changes affecting precursor materials under REACH guidelines, with collaborative industry efforts underway to standardize testing methodologies by Q3 2024.
(1242137-15-0)
A: CAS 1242137-15-0 is a unique identifier for a specific chemical compound. It helps precisely identify the substance's chemical structure and properties in global databases.
A: Verified suppliers for CAS 1242137-15-0 are listed on specialized chemical sourcing platforms like ChemSpider and Reaxys. Cross-check certifications and batch analysis reports for legitimacy.
A: Contact manufacturers directly through their websites or industry portals like EC21. Provide details like purity requirements, quantity, and application to get accurate quotes.
A: Reputable suppliers must offer CoA (Certificate of Analysis), SDS, and synthesis method details. Ensure all documents specify the unique CAS registry number and purity levels.
A: Yes, most manufacturers offer custom bulk synthesis of CAS 1242137-15-0. Request MOQ details and scalability options during initial inquiries.